Amlodipinevalsartanhydrochlorothiazide: Fixed-dose combination in hypertension

American Journal of Cardiovascular Drugs

Volumn 9, Issue 6, 2009, Pages 411-418

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; DRUG METABOLITE; EXFORGE HCT; HYDROCHLOROTHIAZIDE; UNCLASSIFIED DRUG; VALERYL 4 HYDROXYVALSARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BUTIZIDE; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

AREA UNDER THE CURVE; BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ETHNICITY; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG COMBINATION; PHASE 3 CLINICAL TRIAL;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; TETRAZOLES; VALINE;

EID: 71149106247     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11204350-000000000-00000     Document Type: Review

References (22)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report.JAMA2003 May 21; 289 (19): 2560-2572
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society ofCardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-1536
3. World Health Organization. Cardiovascular diseases fact sheet [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs317/en/ index.html [Accessed 2009 Sep 9]
4. Novartis Pharmaceuticals Corporation. Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022314lbl.pdf [Accessed 2009 Sep 1]
5. Haria M, Wagstaff AJ. Amlodipine: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995; 50 (5): 896]. Drugs 1995; 50 (3): 560-586
6. Markham A, Goa KL. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54 (2): 299-311 (Pubitemid 27361837)
7. Thürmann PA. Valsartan: A novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 2000 Jan; 1 (2): 337-350
8. Wagstaff AJ. Valsartan/hydrochlorothiazide: A review of its use in the management of hypertension. Drugs 2006; 66 (14): 1881-1901
9. Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide in the treatment of essential hypertension. Drugs 2003; 63 (19): 2013-2026
10. Padilla MC, Armas-Herná ndez MJ, Herná ndez RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther 2007 Mar-Apr; 14 (2): 154-160
11. Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022314s000-ClinPharmR.pdf [Accessed 2009 Sep 10]
12. Calhoun DA, Lacourcière Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension 2009 Jul; 54 (1): 32-39
13. Lacourciere Y, Glazer RD, Yen J, et al. Twenty-four hour ambulatory BP control of therapy with amlodipine/valsartan/HCTZ triple combination compared to dual therapy in patients with moderate to severe hypertension [abstract no. P26.301]. J Hypertension 2009; 27 Suppl. 4: S271
14. Lacourciere Y, Glazer R, Crikelair N, et al. Effect of baseline systolic blood pressure on response to triple combination amlodipine/valsartan/ hydrochlorothiazide in patients with moderate-to-severe hypertension [abstract no. P11.294]. J Hypertension 2009; 27 Suppl. 4: S119
15. Calhoun D, Glazer R, Yen J, et al. Effect of age, gender, race and ethnicity on efficacy of amlodipine/valsartan/hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension [abstract no. P11.296]. J Hypertension 2009; 27 Suppl. 4: S119
16. Zappe DH, Crikelair N, Papst CC, et al. Efficacy of amlodipine/valsartan/ hydrochlorothiazide triple combination in patients whose blood pressure was not controlled with dual combinations: The PROMPT extension study [abstract no. P11.304]. J Hypertension 2009; 27 Suppl. 4: S121
17. White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: Increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The Valsartan hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve optimal Therapeutic Effect (Val-DICTATE) trial. J Clin Hypertension 2008 Jun; 10 (6): 450-458
18. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND study. J Hum Hypertension 2009 Jul; 23 (7): 479-489
19. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/ valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: A randomized, double-blind, multicenter study: The EX-EFFeCTS study. J Am Society Hypertension 2008 Jul; 2 (4): 294-302
20. Braun N, Handrock R, Klebs S, et al. Triple combination of valsartan, amlodipine, and HCTZ provides effective reduction of blood pressure in patients with hypertension not controlled by dual therapy with amlodipine plus valsartan or valsartan plus HCTZ [abstract no. P26.306]. 19th European Meeting of Hypertension; 2009 Jun 12-16; Milan
21. Food and Drug Administration. Center for Drug Evaluation and Research. Medical review(s) [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2009/022314s000-MedR.pdf [Accessed 2009 Sep 16]
22. Novartis Europharm Limited. Exforge HCT film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/exforge-hct/emea-combined-h1068en. pdf [Accessed 2009 Nov 16]